Zynex reports Q4 EPS (2c), consensus 9c

Reports Q4 revenue $46.0M, consensus $53.65M. “In the Q4 we continued our steady growth in orders and delivered another year of revenue growth and profitability,” said Thomas Sandgaard, President and CEO of Zynex (ZYXI). “We generated $12.7M of positive cash flow from operations and $10.9M of Adjusted EBITDA in 2024. Our Q4 revenue was less than expected. The shortfall was due to slower than normal payments from certain payers and we were recently notified that Tricare has temporarily suspended payments as they review prior claims. We continue to be in-network and have maintained good relations with Tricare. We have a meeting with Tricare in April and believe we have good evidence to get payments reinstated. TriCare currently represents approximately 20-25% of our annual revenue. As directed by Tricare, we continue to support both existing patients and new patients as we receive their prescriptions.”